Google
INBX — INHIBRX BIOSCIENCES, INC. (Healthcare >> Biotechnology)
INBX FAQ
What is INBX's ROE?
INHIBRX BIOSCIENCES, INC. reports a Return on Equity (ROE) of 618.90%.
What is INBX's dividend yield?
INHIBRX BIOSCIENCES, INC. offers a dividend yield of 0.00%.
What is INBX's Deepscope Quality Score?
Deepscope rates INBX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy INBX?
Deepscope's AI Timing Score for INBX is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does INBX belong to?
INHIBRX BIOSCIENCES, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 89.13
Price
2.12
(2.44%)
Day Change
|
|
|---|
INBX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 89.13 |
| PBV / Sector |
-60.69 / 4.75
|
| Earning Per Share | -9.09 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
44.96 M
GREAT
|
| Average 1W Daily Value |
25.76 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-06-09 09:40:00 |
| Symbol | INBX |
| Name | INHIBRX BIOSCIENCES, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 14.67 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,276.54 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037
Phone: 858 795 4220
Website: https://inhibrx.com
Employees: 109
Sector: Healthcare >> Biotechnology
Description: Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
